1269646-23-2

Basic information

• Product Name: 2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole
• Synonyms: 2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole;2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole
• CAS NO: 1269646-23-2
• Molecular Weight: 400.401
• Mol File: 1269646-23-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole(1269646-23-2)
• EPA Substance Registry System: 2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole(1269646-23-2)

Safety Data

• Hazardous Substances Data: 1269646-23-2(Hazardous Substances Data)

Usage

General Description

The chemical "2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole" is a complex compound designed for specific pharmaceutical or research purposes. It contains a boron-based moiety, which is often used in organic chemistry reactions. The presence of imidazole in the molecule suggests potential biological activity, as imidazoles are found in many medicinal compounds. Additionally, the trimethylsilanyl-ethoxymethyl group indicates that this chemical may have potential applications in synthetic organic chemistry. Overall, its unique structure suggests that it may have diverse applications in various fields, such as pharmaceuticals, materials science, and chemical synthesis.

Upstream product

• 934744-50-0 2-(4-bromophenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 176961-53-8 2-(4-bromophenyl)-1H-imidazole 
• 623-00-7 4-bromobenzenecarbonitrile 

Downstream Products

• 1269646-25-4 (S)-4-isopropyl-3-(3-(4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)oxazolidin-2-one 
• 1269643-37-9 (S)-3-(3-(4-(1H-imidazol-2-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)-4-isopropyloxazolidin-2-one 
• 1269643-42-6 (S)-3-(3-(4-(1H-imidazol-2-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)-4-phenyloxazolidin-2-one 
• 1618658-98-2 4-(5-(4-(1H-imidazol-2-yl)phenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide 

Relevant articles and documents

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen

Triple negative breast cancer (TNBC) remains a serious unmet medical need with discouragingly high relapse rates. We report here the synthesis and structure-activity relationship (SAR) of a novel series of 2,4,5-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines with potent activity against TNBC tumor cell lines. These compounds were discovered from a TNBC phenotypic screen and possess a unique dual inhibition profile targeting TTK (mitotic exit) and CLK2 (mRNA splicing). Design and optimization, driven with a TNBC tumor cell assay, identified potent and selective compounds with favorable in vitro and in vivo activity profiles and good iv PK properties. This cell-based driven SAR produced compounds with strong single agent in vivo efficacy in multiple TNBC xenograft models without significant body weight loss. These data supported the nomination of CC-671 into IND-enabling studies as a single agent TNBC therapy.

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS

Compounds of Formula I: and salts thereof in which R1, R2, R2a, R3, n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.